Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib and zoster vaccine immune response in rheumatoid arthritis
2014-000706-34Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jul 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) and herpes zoster (HZ) comparing Tofacitinib + methotrexate + zoster vaccine with Placebo + methotrexate + zoster vaccine (2 arms). Primary endpoint: Fold increase from vaccination baseline in VZV antibodies. Started Jul 2014; status: completed.
02
Drugs
tofacitinibmethotrexate
03
Conditions
rheumatoid arthritis (RA)herpes zoster (HZ)
Beyond the preview
Go deeper on 2014-000706-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000706-34.